Effect of biologics targeting interleukin-23/-17 axis on subclinical atherosclerosis: results of a pilot study. Marovt M, Marko PB, Pirnat M, Ekart R, et al. Clin Exp Dermatol 2020;45:560-564.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Marovt M, Marko PB, Pirnat M, Ekart R, et al. Effect of biologics targeting interleukin-23/-17 axis on subclinical atherosclerosis: results of a pilot study. Clin Exp Dermatol 2020;45:560-564.
PMID: 31961453